radiopharmaceutical development

bring ideas to life – for a better health worldwide Radiopharmaceuticals CDMO / CMOProducts See what makes the Difference Radelumin® is indicated for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings: • Primary staging of patients with high-risk PCa prior to primary curative therapy• Suspected PCa recurrence in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy.More Radiopharmaceutical Partner from Development to Global Supply ABX is a trusted partner in radiopharmaceutical innovation, combining 30 years of experience with expertise across development, manufacturing, regulatory support and global supply. Our integrated portfolio of radiopharmaceuticals, CDMO / CMO services and products helps bring.

analytical procedure developmentglobal distributionGMP manufacturingproject managementQC method developmentradiolabelingregulatory supporttech transfer

Archeus Technologies is a radiopharmaceutical company developing differentiated radiopharmaceutical therapies (RPT) for some of the most difficult-to-treat cancers. Its growing pipeline includes novel RPT agents and companion diagnostic assets with the potential to provide curative responses for patients with advanced disease.

clinical trial designpreclinical researchradioanalytical methodsradiolabelingtargeted radionuclide therapy

Cyclomedica is a global nuclear medicine and molecular imaging provider based in Australia, operating under Cyclopharm Limited (ASX:CYC). Its flagship product, Technegas®, is a diagnostic lung imaging technology for visualisation of pulmonary ventilation and lung function, distributed in 65 countries. Technegas gained approval for distribution in the USA, with US market debut in Q4 2023 following USFDA approval.

functional lung imagingmedical equipment developmentmolecular imagingnuclear medicinePET imagingSPECT imaging

Jubilant Radiopharma is a global pharmaceutical company specializing in nuclear medicine, focused on developing, manufacturing, commercializing and distributing diagnostic and therapeutic radiopharmaceuticals. It combines the clinical expertise of a global manufacturer with a leading radiopharmacy network in the United States, serving millions of patients every year. A Jubilant Pharmova Company.

commercializationdistributionmanufacturingresearch and drug development